Actively Recruiting
Randomized Trial Comparing Implantable Gestrinone Pellets and Daily Oral Dienogest for Endometriosis Treatment
Led by Bio Meds Pharmaceutica Ltda · Updated on 2026-10-20
70
Participants Needed
4
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of implantable Gestrinone compared to oral Dienogest in relieving symptoms related to endometriosis. This phase 4 randomized controlled trial involves adult female patients aged 18 to 45 years with menstrual age who seek treatment to ease complaints of endometriosis. The study aims to compare these two therapies regarding pain severity, uterine bleeding, systemic effects, lesion regression, body composition, quality of life, and sexual function. Participants will be randomly assigned to one of two groups one receiving subcutaneous implantation of Gestrinone pellets in the gluteal region at a dose of 1.6 mgkg body weight, repeated after six months, and the other receiving oral Dienogest daily at 2 mg for 12 months. Follow-up visits are scheduled at 1 week, then 1, 3, 6, 9, and 12 months after treatment begins to evaluate effects over time. During the study, participants will have assessments including pain severity scales, uterine bleeding scores, blood tests for hormonal and liver function, ultrasound imaging for lesion and endometrial thickness evaluation, body composition analysis, and questionnaires for quality of life and sexual function. Researchers will monitor safety and adverse effects throughout, using statistical methods to compare outcomes between groups over the 12-month treatment period.
CONDITIONS
Brief Title
Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis
Research Team
A
André V. A. Florentino, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here